AQST - アクエスティブ・セラピュ―ティクス (Aquestive Therapeutics Inc.) アクエスティブ・セラピュ―ティクス

 AQSTのチャート


 AQSTの企業情報

symbol AQST
会社名 Aquestive Therapeutics Inc (アクエスティブ・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Aquestive Therapeutics Inc. is a specialty pharmaceutical company. The Company is focused on the development of treatments for diseases related to the central nervous system (CNS). Its CNS programs consist of a pipeline of products that include Libervant Sympazan and AQST-117. Libervant is a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures. Sympazan is an oral soluble film formulation of clobazam for the treatment of seizures associated with a rare intractable form of epilepsy known as Lennox-Gastaut Syndrome. AQST-117 is an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The Company’s complex molecule programs consist of AQST-108 and AQST-305 for the treatment of anaphylaxis and neuroendocrine tumors respectively. The Company also has a pipeline of products under partner programs which includes Suboxone and APL-130277 for the treatment of opioid dependence and Parkinson’s disease.   アクエスティブ・セラピュ―ティクスは米国の特殊医薬品企業。主に満たされていない医療ニ―ズに焦点を当て、製品の特定や開発、商業化に従事する。同社の「PharmFilm」は既存の処方薬を直接血流に送達するプラットフォ―ム医薬製剤。医薬品フィルム、個別使用フィルム、患者・医師・介護用のフィルムなどを製造する。本社所在地はニュ―ジャ―ジ―州ウォ―レン。   Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm technology. The firm also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.
本社所在地 30 Technology Drive Warren NJ 07059 USA
代表者氏名
代表者役職名
電話番号 +1 908-941-1900
設立年月日 37987
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 195人
url www.aquestive.com
nasdaq_url https://www.nasdaq.com/symbol/aqst
adr_tso
EBITDA EBITDA(百万ドル) -20.56200
終値(lastsale) 15.775
時価総額(marketcap) 393203343.425
時価総額 時価総額(百万ドル) 369.13940
売上高 売上高(百万ドル) 76.67900
企業価値(EV) 企業価値(EV)(百万ドル) 404.93140
当期純利益 当期純利益(百万ドル) -35.23500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Aquestive Therapeutics Inc revenues increased 35% to $37.3M. Net loss applicable to common stockholders increased from $8.6M to $32.4M. Revenues reflect United States segment increase of 46% to $23.2M Malaysia segment increase of 22% to $33K. Higher net loss reflects Selling General and administrative increase from $10.6M to $41.2M (expense) Research_Development increase of 18% to $12.9M (expense).

 AQSTのテクニカル分析


 AQSTのニュース

   Aquestive Therapeutics (NASDAQ:AQST) Lowered to “Sell” at Zacks Investment Research  2020/10/23 09:08:49 Transcript Daily
Zacks Investment Research downgraded shares of Aquestive Therapeutics (NASDAQ:AQST) from a hold rating to a sell rating in a report published on Monday, Zacks.com reports. According to Zacks, “Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on late-stage proprietary product pipeline which […]
   Aquestive Therapeutics (NASDAQ:AQST) Cut to “Sell” at Zacks Investment Research  2020/10/22 08:03:06 Zolmax News
Zacks Investment Research downgraded shares of Aquestive Therapeutics (NASDAQ:AQST) from a hold rating to a sell rating in a report published on Monday morning, Zacks.com reports. According to Zacks, “Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on late-stage proprietary product pipeline […]
   Aquestive Therapeutics (NASDAQ:AQST) Shares Up 7%  2020/10/21 10:14:47 Zolmax News
Aquestive Therapeutics Inc (NASDAQ:AQST) shot up 7% during trading on Monday . The company traded as high as $5.54 and last traded at $5.38. 768,810 shares were traded during trading, a decline of 18% from the average session volume of 936,964 shares. The stock had previously closed at $5.03. A number of research firms have […]
   Zacks Investment Research Lowers Aquestive Therapeutics (NASDAQ:AQST) to Sell  2020/10/21 06:36:49 Dakota Financial News
Aquestive Therapeutics (NASDAQ:AQST) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday, Zacks.com reports. According to Zacks, “Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on […]
   Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates  2020/09/30 20:51:03 Benzinga
September proved to be a mixed month as far as drug approvals are concerned, with Mallinckrodt PLC (NYSE: MNK ) and Aquestive Therapeutics Inc (NASDAQ: AQST ) facing rejections. PDUFA dates are binary events that invariably serve as make-or-break catalysts for stocks. These dates are deadlines by which the FDA reviews a new drug application before announcing its decision concerning the approvability/non-approvability of the drug. Among the more fortunate ones were GlaxoSmithKline plc (NYSE: GSK ), which got the nod for an expanded indication - hypereosinophilic syndrome. Bristol-Myers Squibb Co's (NYSE: BMY ) leukemia drug also received FDA's blessings, and after several hiccups, Eton Pharmaceuticals Inc's (NASDAQ: ETON ) out-licensed preservative-free allergic conjunctivitis ophthalmic solution managed to win FDA approval . In another notable approval of the month, Roche Holdings AG's (OTC: RHHBY ) Gavreto was vetted to treat adults with metastatic RET fusion-positive non-small cell lung cancer.
   Aquestive Therapeutics (AQST): Strong Industry, Solid Earnings Estimate Revisions  2020/04/15 12:50:00 Zacks Investment Research
Aquestive Therapeutics (AQST) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   Aquestive Therapeutics to Host Investor & Analyst Libervant™ (diazepam) Buccal Film Update Forum at American Epilepsy Society 2019 Annual Meeting  2019/12/04 13:30:10 Yahoo Finance
Aquestive Therapeutics, Inc. (AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients’ unmet needs and solve therapeutic problems, today announced that it will host an investor & analyst update forum related to the Company’s therapeutic
   A Deep Dive Into Aquestive Following The FDA's Approval Of Riluzole  2019/11/26 21:05:03 Benzinga
Aquestive Therapeutics Inc (NASDAQ: AQST ) made a move this week, gaining about 17% Monday after the FDA approved one of its drugs ahead of a Nov. 30 PDUFA action date. The thinly traded, micro-cap stock is little changed on a year-to-date basis, although it has traded in the range of $2.95-$8.54. The company is expected to complete the rolling regulatory submission for another investigational drug before the end of November. Aquestive is a specialty pharma company that primarily focuses on therapies for central nervous system conditions. Founded in 2004 as Monosol Rx, the company changed its name to Aquestive in late 2017. The company offered its shares to the public in July 2018 through a 4.5-million-share IPO priced at $15 per share. The company applies its innovative drug delivery technology PharmFilm to deliver medications through film. It also uses its scientific expertise to redesign important medicines. Source: Aquestive The company has a proprietary commercial product in Sympazan (clobazam) oral film, which is used to treat Lennox-Gastaut syndrome.
   -$0.66 Earnings Per Share Expected for Aquestive Therapeutics Inc (NASDAQ:AQST) This Quarter  2019/11/12 02:33:11 Modern Readers
Analysts expect Aquestive Therapeutics Inc (NASDAQ:AQST) to post ($0.66) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Aquestive Therapeutics’ earnings. The highest EPS estimate is ($0.56) and the lowest is ($0.76). Aquestive Therapeutics posted earnings per share of ($0.56) during the same quarter last year, which would […]
   Analysts Estimate Aquestive Therapeutics (AQST) to Report a Decline in Earnings: What to Look Out for  2019/10/30 14:33:56 Zacks Investment Research
Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Aquestive Therapeutics to Host Investor & Analyst Libervant™ (diazepam) Buccal Film Update Forum at American Epilepsy Society 2019 Annual Meeting  2019/12/04 13:30:10 Yahoo Finance
Aquestive Therapeutics, Inc. (AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients’ unmet needs and solve therapeutic problems, today announced that it will host an investor & analyst update forum related to the Company’s therapeutic
   A Deep Dive Into Aquestive Following The FDA's Approval Of Riluzole  2019/11/26 21:05:03 Benzinga
Aquestive Therapeutics Inc (NASDAQ: AQST ) made a move this week, gaining about 17% Monday after the FDA approved one of its drugs ahead of a Nov. 30 PDUFA action date. The thinly traded, micro-cap stock is little changed on a year-to-date basis, although it has traded in the range of $2.95-$8.54. The company is expected to complete the rolling regulatory submission for another investigational drug before the end of November. Aquestive is a specialty pharma company that primarily focuses on therapies for central nervous system conditions. Founded in 2004 as Monosol Rx, the company changed its name to Aquestive in late 2017. The company offered its shares to the public in July 2018 through a 4.5-million-share IPO priced at $15 per share. The company applies its innovative drug delivery technology PharmFilm to deliver medications through film. It also uses its scientific expertise to redesign important medicines. Source: Aquestive The company has a proprietary commercial product in Sympazan (clobazam) oral film, which is used to treat Lennox-Gastaut syndrome.
   -$0.66 Earnings Per Share Expected for Aquestive Therapeutics Inc (NASDAQ:AQST) This Quarter  2019/11/12 02:33:11 Modern Readers
Analysts expect Aquestive Therapeutics Inc (NASDAQ:AQST) to post ($0.66) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Aquestive Therapeutics’ earnings. The highest EPS estimate is ($0.56) and the lowest is ($0.76). Aquestive Therapeutics posted earnings per share of ($0.56) during the same quarter last year, which would […]
   Analysts Estimate Aquestive Therapeutics (AQST) to Report a Decline in Earnings: What to Look Out for  2019/10/30 14:33:56 Zacks Investment Research
Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates  2019/08/07 00:05:09 Zacks Investment Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -22.39% and 6.45%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

 関連キーワード  (医薬品 米国株 アクエスティブ・セラピュ―ティクス AQST Aquestive Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)